MaRS Innovation recently announced the launch of two new projects targeting the development of new therapeutics for cystic fibrosis (CF) and respiratory syncytial virus (RSV). These projects are part of LAB150, MaRS Innovation’s joint venture with Evotec AG to support collaboration among scientists, investors, and pharmaceutical companies to…
News
Eloxx Pharmaceuticals will explore the potential of its lead investigational drug candidate, ELX-02, as a treatment for patients with cystic fibrosis (CF) caused by rare nonsense genetic mutations, in new trials integrated in the European HIT-CF project. “We are extremely excited to be participating in the HIT-CF research…
NetNoggin has launched a new cystic fibrosis (CF) market research report to highlight patient and caregiver experiences and their perspectives about the gaps in CF research, the company announced. NetNoggin is a company that specializes in pharmaceutical marketing. The new offering, called NetNog: #genesis Cystic Fibrosis Patient and Caregiver…
Despite being commonly found in patients with cystic fibrosis-related diabetes, the bacteria Stenotrophomonas maltophilia cannot be considered as an independent risk factor for developing CFRD, study says. The study, “Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from the UK CF Registry,”…
Exposing cystic fibrosis (CF) patients to high levels of oxygen through hyperbaric oxygen treatment may make Pseudomonas aeruginosa bacterial aggregates more sensitive to antibiotics like tobramycin and easier to eradicate from the lungs, a study in patient-derived bacterial cultures reports. The study, “Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from…
Results from a Phase 3 trial demonstrate that Symkevi (tezacaftor and ivacaftor combo), known as Symdeko in the U.S., is safe and can effectively improve lung clearance in children, from 6 to 11 years old, with cystic fibrosis (CF). With these results, Vertex Pharmaceuticals — the…
Later this month, the Cystic Fibrosis Foundation (CFF) will host ResearchCon, its first virtual event dedicated to cystic fibrosis (CF) science and research. Some 480 people have registered for the Feb. 28 online conference, with at least 300 of them likely to participate, said Shellie Byrum, director of community…
Emily’s Hope and Cisco have raised more than $1 million as part of Great Strides – a Cystic Fibrosis Foundation (CFF) fundraiser – becoming its top-performing national corporate team for the event. The Great Strides walk event is CFF’s largest national fundraiser that seeks to raise awareness about cystic…
“Five Feet Apart,” an upcoming romantic movie about two teens with cystic fibrosis (CF) who fall in love while undergoing treatment, now has a marketing partner — rue21. The film is set to open at theaters around the U.S. on March 15, a press release states. An apparel and…
Tobramycin, an antibiotic commonly used against Pseudomonas aeruginosa bacteria, reduces the bacteria’s load of virulence factors that impair the function of the CFTR (cystic fibrosis transmembrane conductance regulator) protein, a new study shows. The study, “Tobramycin reduces key virulence determinants in the proteome of Pseudomonas aeruginosa outer membrane vesicles,” was published in the journal…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.